Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Feb;21(1):177-9.
doi: 10.3346/jkms.2006.21.1.177.

Hydroxyurea induced perimalleolar ulcers

Kavitha Saravu  1 , Praveen Velappan, Naik Lakshmi, Barkur Ananthakrishna Shastry, Joseph Thomas
Affiliations
Case Reports

Hydroxyurea induced perimalleolar ulcers

Kavitha Saravu et al. J Korean Med Sci. 2006 Feb.

Abstract

Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Ulcer over the lateral malleolus (Case 1).
Fig. 2
Fig. 2
Healed scar over the lateral malleolus (Case 1).
Fig. 3
Fig. 3
Ulcer over the lateral malleolus (Case 2).
Fig. 4
Fig. 4
Healed scar over the lateral malleolus (Case 2).
See this image and copyright information in PMC

References

    1. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol. 1975;111:183–187. - PubMed
    1. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy. A unique lichenoid eruption complicating long term therapy with hydroxyurea. J Am Acad Dermatol. 1997;36:178–182. - PubMed
    1. Stahl LR, Silber R. Vasculitic leg ulcers in chronic myelogenous leukemia. Am J Hematol. 1985;78:869–872. - PubMed
    1. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992;19(3) Suppl 9:1–10. - PubMed
    1. Best PJ, Daoud MS, Pittelkow MR, Pettitt RM. Hydroxyurea induced leg ulceration in 14 patients. Ann Intern Med. 1998;128:29–32. - PubMed

Publication types